Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2009

View Archived Issues

Glutamate receptor antagonists have beneficial effects in model of Batten disease / News in Context

Phase III trials show improved sleep maintenance with doxepin

Phase I and II studies find Quadramet-docetaxel combination safe, active in prostate cancer

Alcon discontinues development of anecortave acetate in IOP after phase II trial

Phase II and III studies detail Acurox tolerability and analgesic efficacy

Full study results show OGX-011 meets requirements for further evaluation in prostate cancer

Celgene files NDA in Japan for Revlimid for multiple myeloma

Revotar to initiate phase IIa study of bimosiamose

FDA reviews Oxford Biomedica's phase III TRIST study of TroVax in renal cancer

Spectrum receives complete response letter from the FDA for Zevalin sBLA in NHL

Allos completes recruitment into phase IIb clinical trial of pralatrexate in advanced NSCLC

Novel guanylate cyclase activators emerge from GlaxoSmithKline R&D

Novel radiosensitizers claimed by K. Marcinkowski University of Medical Sciences

Palau Pharma patents histamine H4 receptor antagonists

ZSTK-474 inhibits angiogenesis in vitro and in vivo

Phase II data on ASA-404 in non-small cell lung cancer published

GTx initiates phase I clinical trial of GTx-758 for advanced prostate cancer

Pharmasset nominates PSI-938 as development candidate for HCV infection

Lexicon begins phase II clinical trial of LX-1032 in carcinoid syndrome

Repros provides update on clinical development of Proellex

Rexahn completes enrollment in phase IIa clinical trial of Serdaxin in MDD

FDA and King meet to discuss complete response letter regarding NDA for Remoxy

Inhibiton Therapeutics changes name to AlumiFuel Power

Kineta acquires exclusive commercial rights to Airmid's portfolio of therapeutic compounds

Presidio advances HCV inhibitor PPI-461 toward clinical development, IND-enabling studies under way

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...